Positive Results From Phase 2b Study of Ophthotech Corporation's Novel Anti-PDGF Combination Agent Fovista to be Presented at American Academy of Ophthalmology Retina Subspecialty Day
10/24/2012 9:07:30 AM
PRINCETON, N.J.--(BUSINESS WIRE)--Ophthotech Corporation today announced that data from a large, prospective, randomized, controlled Phase 2b clinical trial of Ophthotech’s FovistaTM anti-PDGF therapy (1.5 mg) in patients with neovascular age-related macular degeneration (wet AMD) will be presented during Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO) on Sat., Nov. 10, 2012 at 9:15 a.m. Central Standard Time (CST) in Chicago at McCormick Place, Arie Crown Theater. The presentation will be given by Pravin U. Dugel, MD, Associate Clinical Professor, Doheny Eye Institute, University of Southern California/Keck School of Medicine and managing partner, Retinal Consultants of Arizona.
comments powered by